Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Inclusion Criteria: * HIV infection * Karnofsky above 80 per cent * Stable ARV since 4 months * CD4 above 200 per mm3 * ARN VIH below 10000 copies per ml * hepatitis B chronic with : positive antigenaemia HBe and negative antiHBe, positive DNA HBV before or under tenofovir treatment, DNA HBV negative or below 10000 copies per ml at W-8. * Previous treatment by tenofovir and lamivudine or emtricitabine more than 6 months Exclusion Criteria: * HIV 2 infection * Hepatitis C or D * Opportunistic infection * Alcool consummation more than 50g/d * Cirrhosis * Pregnancy or plan of pregnancy * Breastfeeding * Immunosuppressive or modulating of the immune response treatment * Other Hepatitis B treatments than tenofovir, lamivudine or emtricitabine since 6 months * Malabsorption * Exclusive HIV therapy with Truvada * Evolutive cancer under chemotherapy